Market Overview

Viveve Medical Shares Plummet After Trial Misses Primary Endpoint


Viveve Medical (NASDAQ: VIVE) shares are trading lower after the company said its LIBERATE-International trial in SUI patients did not not achieve its primary endpoint.

“We are very disappointed that the LIBERATE-International trial did not achieve its primary endpoint,” said CEO Scott Durbin. “We have conducted a full review of the primary efficacy data and expect to receive the complete data results including all secondary end-points in early August.”

Mizuho has also downgraded Viveve Medical from Buy to Underperform and lowered the price target from $4 to $0.20.

Viveve Medical shares were trading down 63.55% at 15 cents in Tuesday's pre-market session. The stock has a 52-week high of $3.71 and a 52-week low of 35 cents.

Related Links:

Harley-Davidson Reports Mixed Q2 Earnings

Stanley Black & Decker Reports Q2 Earnings Beat

Posted-In: News Penny Stocks Markets Movers Trading Ideas


Related Articles (VIVE)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

ProSight Global IPO: What You Need To Know

Lockheed Martin Trades Higher After Q2 Earnings Beat